Ładuje się......
Prostate-Specific Antigen Velocity Risk Count Improves the Specificity of Screening for Clinically Significant Prostate Cancer
OBJECTIVE: Prostate-specific antigen (PSA)-based prostate cancer (CaP) screening has been shown to reduce CaP mortality at the expense of detecting some tumors that might never cause symptoms. PSA velocity (PSAV) has been shown to predict cancer-specific mortality after treatment. Our objective was...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2012
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3338148/ https://ncbi.nlm.nih.gov/pubmed/22296334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2011.10900.x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|